At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 25 enrolled
Drug / intervention
Gabapentin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements in Patients Undergoing Radical Cystectomy
In Brief
A Phase 3 clinical trial evaluating Gabapentin, Placebo, and 1 other intervention for Bladder Carcinoma. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This randomized phase II/III trial studies gabapentin in reducing the need for pain medication in patients with bladder cancer undergoing surgery to remove the bladder and nearby tissue and organs. Gabapentin may reduce the amount of pain medicine required after surgery, improve pain after surgery, and/or reduce the length of hospital stay after surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartApr 2015
Primary CompletionFeb 2018
Study CompletionFeb 2019
TodayJul 2026
First PostedFeb 4, 2015
Enrollment StartApr 22, 2015
Primary CompletionFeb 28, 2018
Study CompletionFeb 28, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 11.4 years ago
Interventions
Gabapentindrug
Given PO
Placeboother
Given PO
Questionnaire Administrationother
Ancillary studies